fofogliflozin

Fofogliflozin (SHR0534) is an orally bioavailable, selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2) developed by Shanghai Hengrui Pharmaceutical for the management of type 2 diabetes mellitus. By targeting SGLT2 in the proximal renal tubules, fofogliflozin prevents the reabsorption of filtered glucose, thereby promoting its excretion in the urine and reducing plasma glucose levels. This mechanism operates independently of insulin secretion or action, offering a complementary approach to traditional antidiabetic therapies. Fofogliflozin has undergone Phase 1 and Phase 2 clinical evaluations in China, where it demonstrated dose-dependent increases in urinary glucose excretion and significant reductions in HbA1c levels in patients with type 2 diabetes.

Other names

fuglefanFugliefanFuglifan福格列泛